Schulman IRB To Launch Central Oncology Review (COR) Division In November
Cincinnati, OH and Durham, NC – October 31, 2016 – Schulman IRB, the industry-leading central IRB in customer service and technology, will launch its new Central Oncology Review (COR) division at PRIM&R’s 2016 Advancing Ethical Research Conference (AER16).
COR will be led by Michele Russell-Einhorn, JD, VP of Oncology Services, and Judith Carrithers, Director of Oncology Services. Providing collaborative, flexible IRB review services for organizations conducting oncology research, the launch of COR represents Schulman’s response to requests from institutional research centers looking for a more advanced level of partnership and service integration. COR will feature an IRB roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research.
“As the preeminent meeting for institutional and industry human subject protection experts, AER16 is the perfect place for us to debut COR to the research community,” said Michael Woods, president and CEO of Schulman IRB. “Many of our colleagues are located in oncology research centers and academic institutions – making COR an obvious next step for our team. We’re looking forward to launching this division at the conference, and expect COR to grow into an indispensable part of Schulman’s services.”
Russell-Einhorn, former senior director of Dana-Farber Cancer Institute’s Office for Human Research Studies, also currently serves as co-chair of the Subpart A Subcommittee of the US Department of Health and Human Services (DHHS) Secretary’s Advisory Committee on Human Research Protections. She is a founding member and leader of the IRB Directors group for the National Comprehensive Cancer Network (NCCN).
Carrithers previously served as the assistant dean for human research protection and director of the Human Research Protection Program at Johns Hopkins University School of Medicine.
About Central Oncology Review (COR)
COR provides collaborative, flexible central IRB review services for cancer research centers and their IRBs, offering an advanced level of partnership and service integration. COR’s staff and IRB members include research professionals and clinicians with significant firsthand experience in contemporary oncology research and the associated unique human subject protection requirements. Powered by Schulman IRB’s best-in-class customer service and technology, COR offers unmatched IRB expertise and efficiency in support of institutions at the cutting edge of oncology research. COR launches later in 2016.
For more information, please visit www.centraloncologyirb.com.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
COR will be led by Michele Russell-Einhorn, JD, VP of Oncology Services, and Judith Carrithers, Director of Oncology Services. Providing collaborative, flexible IRB review services for organizations conducting oncology research, the launch of COR represents Schulman’s response to requests from institutional research centers looking for a more advanced level of partnership and service integration. COR will feature an IRB roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research.
“As the preeminent meeting for institutional and industry human subject protection experts, AER16 is the perfect place for us to debut COR to the research community,” said Michael Woods, president and CEO of Schulman IRB. “Many of our colleagues are located in oncology research centers and academic institutions – making COR an obvious next step for our team. We’re looking forward to launching this division at the conference, and expect COR to grow into an indispensable part of Schulman’s services.”
Russell-Einhorn, former senior director of Dana-Farber Cancer Institute’s Office for Human Research Studies, also currently serves as co-chair of the Subpart A Subcommittee of the US Department of Health and Human Services (DHHS) Secretary’s Advisory Committee on Human Research Protections. She is a founding member and leader of the IRB Directors group for the National Comprehensive Cancer Network (NCCN).
Carrithers previously served as the assistant dean for human research protection and director of the Human Research Protection Program at Johns Hopkins University School of Medicine.
About Central Oncology Review (COR)
COR provides collaborative, flexible central IRB review services for cancer research centers and their IRBs, offering an advanced level of partnership and service integration. COR’s staff and IRB members include research professionals and clinicians with significant firsthand experience in contemporary oncology research and the associated unique human subject protection requirements. Powered by Schulman IRB’s best-in-class customer service and technology, COR offers unmatched IRB expertise and efficiency in support of institutions at the cutting edge of oncology research. COR launches later in 2016.
For more information, please visit www.centraloncologyirb.com.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).